Abstract:Background: Methotrexate (MTX) is currently the anchor drug widely used worldwide in the treatment of rheumatoid arthritis (RA). However, the therapeutic response to MTX has been shown to vary widely among individuals, genders and ethnic groups. The reason for this has been not clarified but it is considered to be partially due to several mechanisms in the cellular pathway of MTX including single-nucleotide polymorphisms (SNPs). The purpose of this study was to investigate the allelic frequencies in different ethnic and/or population groups in the 10 polymorphisms of enzyme proteins and transporters related to the MTX response and pharmacokinetics including MTHFR, TYMS, RFC1, FPGS, GGH, ABCB1, ABCC2 and ABCG2 in unrelated healthy Japanese adults and patients with RA. Methods: Ten polymorphisms, methylenetetrahydrofolate reductase (MTHFR) 1298, thymidylate synthase (TYMS) 3'-UTR, reduced folate carrier 1 (RFC1) 80 and-43, folypolyglutamyl synthase (FPGS) 1994, γ-glutamyl hydrolase (GGH) 452 and-401, the ABC transporters (ABCB1 3435, ABCC2 IVS23 + 56, ABCG2 914) of enzyme proteins and transporters related to MTX response and pharmacokinetics in 299 unrelated healthy Japanese adults and 159 Japanese patients with RA were investigated to clarify their contributions to individual variations in response and safety to MTX and establish personalized MTX therapy. SNPs were evaluated using real-time polymerase chain reaction (PCR). Results: Comparison of allelic frequencies in our study with other ethnic/population groups of healthy adults and RA patients showed significant differences in 10 polymorphisms among healthy adults and 7 among RA patients. Allelic frequencies of MTHFR 1298 C, FPGS 1994A and ABCB1 3435 T were lower in Japanese than in Caucasian populations and those of ABCC2 IVS23 + 56 C and ABCG2 914A were higher in Japanese than in Caucasian/European populations in both healthy adults and RA patients. Allelic frequencies of MTHFR 1298 C, GGH-401 T, ABCB1 3435 T, and ABCG2 914A were higher in healthy Japanese adults than in an African population, and those of RFC1 80A, RFC1-43C and ABCC2 IVS23 + 56 C in healthy Japanese adults were lower than in Africans. However, no significant differences were seen in the distribution of allelic frequencies between healthy Japanese adults and RA patients. Conclusion: The variations in allelic frequencies in different ethnic and/or population groups in healthy adults and RA patients may contribute to individual variations in MTX response and toxicity.

Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men

Absence of Ethnic Differences in the Pharmacokinetics of Moxifloxacin, Simvastatin, and Meloxicam among Three East Asian Populations and Caucasians.

Population Pharmacokinetics of Moxifloxacin and Its Concentration–qt Interval Relationship Modeling in Chinese Healthy Volunteers

Population Pharmacokinetics of Modafinil Acid and Estimation of the Metabolic Conversion of Modafinil into Modafinil Acid in 5 Major Ethnic Groups of China

Exploration of pharmacokinetic differences between East Asians and Caucasians: insights from pharmacokinetic studies in healthy subjects

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients

Meta-PK analysis of posaconazole upon dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race

Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 Substrates in Healthy Chinese and European Subjects.

Pharmacokinetics of Moxifloxacin Hydrochloride Tablets in Healthy Volunteers

Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach

Genetic Polymorphisms in Mdr1 and Cyp3a5 and Mdr1 Haplotype in Mainland Chinese Han, Uygur and Kazakh Ethnic Groups

Ethnicity Evaluation of Ferric Pyrophosphate Citrate among Asian and Non-Asian Populations: a Population Pharmacokinetics Analysis

Characterizing the Effects of Race/Ethnicity on Acetaminophen Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling

Population Pharmacokinetic Modelling for Enterohepatic Circulation of Mycophenolic Acid in Healthy Chinese and the Influence of Polymorphisms in Ugt1a9

Differences in Genotype and Allele Frequency Distributions of Polymorphic Drug Metabolizing Enzymes CYP2C19 and CYP2D6 in Mainland Chinese Mongolian, Hui and Han Populations

Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects

Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients

Molecular Basis of Ethnic Differences in Drug Disposition and Response

Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population

Structure-Based Analysis of Cefaclor Pharmacokinetic Diversity According to Human Peptide Transporter-1 Genetic Polymorphism